Clinical Trials on Multiple Myeloma in Relapse

Total 3802 results

Novartis Pharmaceuticals

Completed

Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma (MACS1271)

Refractory Multiple Myeloma | Multiple Myeloma in Relapse | Relapsed and Bortezomib Refractory Multiple Myeloma

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

Acute Lymphoblastic Leukemia, in Relapse | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory | Acute Lymphocytic Leukaemia Refractory

China
Instituto de Seguridad y Servicios Sociales de...

Unknown

Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans (MM-POM-2018)

Refractory Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma Progression

Mexico
Lawson Health Research Institute
The Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health System

Active, not recruiting

Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma (RithMM)

Multiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage III

Canada
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory | Relapsed Acute Myeloid Leukemia

United States
Oncotherapeutics

Not yet recruiting

A Trial of Selinexor, Ruxolitinib and Methylprednisolone (KPT-IST-391)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory
Marcela V. Maus, M.D.,Ph.D.

Recruiting

TriPRIL CAR T Cells in Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Multiple Myeloma in Relapse

United States
All4Cure
GlaxoSmithKline

Recruiting

Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma, Refractory

United States
Dana-Farber Cancer Institute
Bristol-Myers Squibb

Not yet recruiting

Marizomib Central Nervous System (CNS)

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

United States
Andrew Yee, MD
Janssen Research & Development, LLC; Amgen

Recruiting

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Multiple Myeloma | Refractory Multiple Myeloma | Relapse | Multiple Myeloma in Relapse

United States
National Cancer Institute (NCI)

Completed

Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma

Stage II Multiple Myeloma | Stage III Multiple Myeloma | Multiple Myeloma in Relapse

United States
Mundipharma-EDO GmbH

Terminated

Tinostamustine Conditioning and Autologous Stem Cell (TITANIUM1)

Multiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Progression

Switzerland, United States, Norway
Harpoon Therapeutics

Active, not recruiting

A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and PK of HPN217 in Patients With R/R MM

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma of Bone

United States, Spain, France
Aibin Liang，MD，Ph.D.
CARsgen Therapeutics Co., Ltd.

Recruiting

Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Relapsed and/or Refractory Multiple Myeloma | Plasma Cell Leukemia in Relapse

China
The First Affiliated Hospital of Xiamen University

Recruiting

All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
Oncotherapeutics

Not yet recruiting

A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory
Dong-A University Hospital

Not yet recruiting

Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM (KMM-KCd)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory
Amsterdam UMC, location VUmc

Not yet recruiting

Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative Study (POMAlternative)

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory
Luminary Therapeutics
The Cleveland Clinic; Case Western Reserve University

Recruiting

LMY-920 for Treatment of Relapsed or Refractory Myeloma (LMY-920-002)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

United States
Tel-Aviv Sourasky Medical Center
Weizmann Institute of Science

Recruiting

Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

Israel
Tel-Aviv Sourasky Medical Center

Recruiting

Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib (IPoD-790)

Refractory Multiple Myeloma | Multiple Myeloma in Relapse

Israel
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
TJ Biopharma Co., Ltd.

Active, not recruiting

TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Multiple Myeloma in Relapse

China, Taiwan
TJ Biopharma Co., Ltd.

Active, not recruiting

TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Multiple Myeloma in Relapse

China, Taiwan
Alliance Foundation Trials, LLC.
Pharmacyclics LLC.

Active, not recruiting

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Multiple Myeloma in Relapse

United States
Ajai Chari
Celgene Corporation

Completed

Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

United States
Zhejiang University
Hangzhou Cheetah Cell Therapeutics Co., Ltd

Recruiting

BCMA CAR-NK For Patients With RRMM

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
920th Hospital of Joint Logistics Support Force...

Recruiting

Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
Chongqing Precision Biotech Co., Ltd

Enrolling by invitation

Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
Poitiers University Hospital
Sanofi; Celgene; Amgen; Intergroupe Francophone du Myelome

Active, not recruiting

Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

France
Gadeta B.V.

Active, not recruiting

A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

United States
Cogent Biosciences, Inc.
Seagen Inc.

Terminated

Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Multiple Myeloma in Relapse

United States
Celgene
Celgene Corporation

Completed

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Multiple Myeloma in Relapse

United States, Australia
Ciusss de L'Est de l'Île de Montréal

Unknown

Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) (GLIDE)

Relapsed Multiple Myeloma | Relapsed Non Hodgkin Lymphoma | Hematologic Cancer | Relapsed Adult AML | Relapse Leukemia | Relapsed Adult ALL | Relapsed CLL | Relapsed Hodgkin's Lymphoma | Relapsed Myelodysplastic Syndromes

Canada
Senesco Technologies, Inc.

Unknown

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

Multiple Myeloma | Plasma Cell Leukemia | Multiple Myeloma in Relapse | Mantle Cell Lymphoma in Relapse | Diffuse Large B Cell Lymphoma in Relapse | Other B Cell Lymphoma in Relapse

United States, South Africa
XuYan

Recruiting

Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
Dong-A University Hospital
Amgen

Not yet recruiting

Long-term KRd in Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory
Dana-Farber Cancer Institute
National Institutes of Health (NIH); Genus Oncology, LLC

Withdrawn

GO-203-2C + Bortezomib For Relapsed Or Refractory MM

Multiple Myeloma | Refractory Multiple Myeloma | Multiple Myeloma in Relapse

United States
Alfred Chung, MD
Merck Sharp & Dohme LLC

Terminated

Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies

Multiple Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

United States
Amgen

Active, not recruiting

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

Relapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid Leukemia

United States, Australia, Japan, Germany, Canada
Fortis Therapeutics, Inc.

Completed

A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma With Failed Remission

United States
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Unknown

CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma Progression

China
Dana-Farber Cancer Institute
Novartis

Completed

A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma (PanRVD)

Multiple Myeloma in Relapse

United States
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma

Refractory Multiple Myeloma | Multiple Myeloma in Relapse | Plasmacytoid; Lymphoma

China
Assistance Publique - Hôpitaux de Paris

Active, not recruiting

Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma (CONFIRM)

Multiple Myeloma in Relapse

France
Institut Cancerologie de l'Ouest

Terminated

Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma Relapse (TOMMY)

Multiple Myeloma in Relapse

France
PETHEMA Foundation

Recruiting

Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes

Multiple Myeloma in Relapse

Spain
Peng Liu
Shanghai East Hospital; Hrain Biotechnology

Unknown

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM

Multiple Myeloma in Relapse | Multiple Myeloma Progression

China
Omar Nadeem, MD
Takeda

Recruiting

Ixazomib + Pomalidomide + Dexamethasone In MM

Multiple Myeloma | Multiple Myeloma in Relapse

United States
Canadian Myeloma Research Group

Completed

A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma in Relapse

Canada

Clinical Trials on Multiple Myeloma in Relapse

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations